Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists

GLP-1RA use was associated with a lower incidence of liver and pancreatic cancer, with no increased risk observed for other major cancers. As these medications become more widely used, further research is warranted to better define their long-term cancer-related safety profile.